Access to Medicines for Parkinson's Disease in Kenya: A Qualitative Exploration.
Africa
access
affordability
availability
medication
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
revised:
15
07
2024
received:
08
01
2024
accepted:
27
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
aheadofprint
Résumé
The accessibility of Parkinson's disease medicines is limited across sub-Saharan Africa, which can have negative health, social and financial consequences for people with Parkinson's disease and their families. However, there is a stark gap in the literature regarding the impact of poor access to medicines on individuals. The study objective was to understand the accessibility of Parkinson's disease medicines in Kenya from the perspective of people with Parkinson's disease, their caregivers and neurologists. In-depth qualitative interviews were conducted with 55 people with Parkinson's disease, 23 caregivers and 8 neurologists to understand their experience regarding challenges with accessing Parkinson's disease medicines and the health, social and financial impact of poor availability and affordability. Medicines for Parkinson's disease were deemed to be largely unavailable and unaffordable across Kenya. People with Parkinson's disease, caregivers and neurologists expressed the financial burden caused by long-term treatment in the absence of health insurance coverage. Further, barriers accessing medicines negatively impacted symptom control, social relations, and quality of life. Access to Parkinson's disease medicines in Kenya is limited, with severe implications for symptom management and quality of life. People with Parkinson's disease should be able to access and afford the medicines they need to manage their condition.
Sections du résumé
BACKGROUND
BACKGROUND
The accessibility of Parkinson's disease medicines is limited across sub-Saharan Africa, which can have negative health, social and financial consequences for people with Parkinson's disease and their families. However, there is a stark gap in the literature regarding the impact of poor access to medicines on individuals.
OBJECTIVES
OBJECTIVE
The study objective was to understand the accessibility of Parkinson's disease medicines in Kenya from the perspective of people with Parkinson's disease, their caregivers and neurologists.
METHODS
METHODS
In-depth qualitative interviews were conducted with 55 people with Parkinson's disease, 23 caregivers and 8 neurologists to understand their experience regarding challenges with accessing Parkinson's disease medicines and the health, social and financial impact of poor availability and affordability.
RESULTS
RESULTS
Medicines for Parkinson's disease were deemed to be largely unavailable and unaffordable across Kenya. People with Parkinson's disease, caregivers and neurologists expressed the financial burden caused by long-term treatment in the absence of health insurance coverage. Further, barriers accessing medicines negatively impacted symptom control, social relations, and quality of life.
CONCLUSIONS
CONCLUSIONS
Access to Parkinson's disease medicines in Kenya is limited, with severe implications for symptom management and quality of life. People with Parkinson's disease should be able to access and afford the medicines they need to manage their condition.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Economic and Social Research Council
ID : ES/J500082/1
Informations de copyright
© 2024 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Schiess N, Cataldi R, Okun MS, et al. Six action steps to address global disparities in Parkinson disease: a World Health Organization priority. JAMA Neurol 2022;79:929–936. https://doi.org/10.1001/jamaneurol.2022.1783.
World Health Organization. Parkinson Disease: a Public Health Approach. Geneva: Technical Brief; 2022.
Cardoso F. Difficulties of access to diagnostic methods and therapies in movement disorders: a call to action. Mov Disord Clin Pract 2023;11:7–9. https://doi.org/10.1002/mdc3.13904.
Fothergill‐Misbah N, Walker R, Kwasa J, et al. “Old people problems”, uncertainty and legitimacy: challenges with diagnosing Parkinson's disease in Kenya. Social Sci Med 2021;282:114148:1–8. https://doi.org/10.1016/j.socscimed.2021.114148.
World Health Organization (WHO). Atlas: Country Resources for Neurological Disorders. 2nd ed. Geneva: World Health Organization; 2017.
World Health Organization. Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031. Geneva: World Health Organization; 2023.
Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397(10291):2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X.
Fothergill‐Misbah N. The lived experience of stigma and parkinson's disease in Kenya: a public health challenge. BMC Public Health 2023;23(1):364. https://doi.org/10.1186/s12889-023-15278-7.
Mshana G, Dotchin CL, Walker RW. 'We call it the shaking illness': Perceptions and experiences of Parkinson's disease in rural northern Tanzania. BMC Public Health 2011;11(219):1–8. https://doi.org/10.1186/1471-2458-11-219 [published Online First: 2011/04/12].
Mokaya J, Gray WK, Carr J. Beliefs, knowledge and attitudes towards Parkinson's disease among a Xhosa speaking black population in South Africa: a cross‐sectional study. Parkinsonism Relat Disord 2017;41:51–57. https://doi.org/10.1016/j.parkreldis.2017.05.009.
Kaddumukasa M, Kakooza A, Kaddumukasa MN, Ddumba E, Mugenyi L, Sajatovic M, Katabira E. Knowledge and attitudes of Parkinson's disease in rural and urban Mukono District, Uganda: a cross‐sectional, community‐based study. Parkinson's Dis 2015;2015(196150):1–7. https://doi.org/10.1155/2015/196150.
Okubadejo NU, Ojo OO, Wahab KW, et al. A Nationwide survey of Parkinson's disease medicines availability and affordability in Nigeria. Mov Disord Clin Pract 2019;6(1):27–33. https://doi.org/10.1002/mdc3.12682.
Mokaya J, Dotchin CL, Gray WK, Hooker J, Walker RW. The accessibility of Parkinson's disease medication in Kenya: results of a National Survey. Mov Disord Clin Pract 2016;3:376–381. https://doi.org/10.1002/mdc3.12294.
Dotchin CL, Msuya O, Walker RW. The challenge of Parkinson's disease management in Africa. Age Ageing 2007;36(2):122–127. https://doi.org/10.1093/ageing/afl172.
Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plan 2013;28(7):692–704. https://doi.org/10.1093/heapol/czs108 [published Online First: 20121122].
Cham M, Sefah I, Oppon K, et al. Availability of Parkinson's disease medicines in Ghana: a national survey [abstract]. Mov Disord 2019;34:S34.
Hamid E, Ayele BA, Massi DG, et al. Availability of therapies and Services for Parkinson's disease in Africa: a continent‐wide survey. Mov Disord 2021;36(10):1393–2407. https://doi.org/10.1002/mds.28669.
Fothergill‐Misbah N. Lived Experiences of Parkinson's Disease in Kenya: Sociality, Improvisation and Hope. Newcastle upon Tyne: Newcastle University Theses; 2020.
Fothergill‐Misbah N, Moffatt S, Mwithiga H, Hampshire K, Walker R. The role of support groups in the management of Parkinson's disease in Kenya: sociality, information and legitimacy. Glob Public Health 2021;17:1–11. https://doi.org/10.1080/17441692.2021.1954227.
Reeves S, Kuper A, Hodges BD. Qualitative research methodologies: ethnography. BMJ 2008;337(a1020):512–514. https://doi.org/10.1136/bmj.a1020.
Braun V, Clarke V. Thematic Analysis: A Practical Guide. United Kingdom: SAGE Publications; 2021.
Dotchin C, Jusabani A, Walker R. Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania. J Neurol 2011;258(9):1649–1656. https://doi.org/10.1007/s00415-011-5988-y.
Cheong JL‐Y, Goh ZHK, Marras C, et al. The impact of COVID‐19 on access to Parkinson's disease medication. Mov Disord 2020;35(12):2129–2133. https://doi.org/10.1002/mds.28293.
Salari P, Di Giorgio L, Ilinca S, et al. The catastrophic and impoverishing effects of out‐of‐pocket healthcare payments in Kenya, 2018. BMJ Glob Health 2019;4(6):1–13. https://doi.org/10.1136/bmjgh-2019-001809.
Ogunniyi A. Treatment of parkinsonian syndromes in developing countries. Afr J Med Med Sci 1997;26(1–2):101–103.
van Olmen J, Ku GM, Bermejo R, Kegels G, Hermann K, van Damme W. The growing caseload of chronic life‐long conditions calls for a move towards full self‐management in low‐income countries. Globalization Health 2011;7(38):1–10. https://doi.org/10.1186/1744-8603-7-38.
Grady PA, Gough LL. Self‐management: a comprehensive approach to management of chronic conditions. Am J Public Health 2014;104(8):e25–e31. https://doi.org/10.2105/AJPH.2014.302041 [published Online First: 2014/06/12].
Abdulrehman MS, Woith W, Jenkins S, et al. Exploring cultural influences of self‐Management of Diabetes in coastal Kenya: an ethnography. Global Qual Nurs Res 2016;3:1–9. https://doi.org/10.1177/2333393616641825 [published Online First: 2017/05/04].
Marsland R. (bio)sociality and HIV in Tanzania: finding a living to support a life. Med Anthropol Q 2012;26(4):470–485. https://doi.org/10.1111/maq.12002.
Mugo MG. The impact of health insurance enrollment on health outcomes in Kenya. Health Econ Rev 2023;13(1):42. https://doi.org/10.1186/s13561-023-00454-7.
Ministry of Health. Kenya Essential Medicines List 2023. Vol 2023. Nairobi, Kenya: Ministry of Health; 2023.
World Health Organization. Selection of Essential Medicines at the Country Level: Using the WHO Model List of Essential Medicines to Update a National Essential Medicines List. Geneva: World Health Organization; 2020.
Green A, Lyus R, Ocan M, Pollock AM, Brhlikova P. Registration of essential medicines in Kenya, Tanzania and Uganda: a retrospective analysis. J R Soc Med 2023;116(10):331–342. https://doi.org/10.1177/01410768231181263.
World Health Organization. Improving access to medicines for neurological disorders. Geneva; 2024. Licence: CC BY‐NC‐SA 3.0 IGO.
Cilia R, Akpalu A, Sarfo FS, et al. The modern pre‐levodopa era of Parkinson's disease: insights into motor complications from sub‐Saharan Africa. Brain 2014;137(10):2731–2742. https://doi.org/10.1093/brain/awu195.